Statement

Medicines pay-for-delay back under the microscope

21 January 2011 – Patent settlements come under scrutiny with the European Commission launching a second monitoring exercise. These pay-for-delay settlements can prevent people from accessing the medicines they need by artificially extending the monopoly of a blockbuster medicine. Last summer the US House of Representatives in its ‘Preserve Access to Generic Medicines Act’ condemned these settlements as anti-competitive and against the public interest. Patient and consumer groups need to be vigilant in monitoring the European Commission’s work on anti-competitive pharmaceutical practices and support its efforts to ensure health in all policies.

Health Action International (Europe)

For more information, please contact Katrina@haieurope.org

This document arises from the HAI Europe’s Operating Grant 2011, which has received funding from the European Union, in the framework of the Health programme. The views expressed in this publication are those of the author, who is solely responsible for its content. The Executive Agency for Health & Consumers is not responsible for any use of the information herein.